Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.

Joshua F BakerCatherine BakewellAra DikranianGordon LamJacqueline O'BrienPage C MooreMiao YuPeter HurKarim Richard Masri

Published in: Rheumatology and therapy (2024)

In this real-world population of patients with RA initiating IFX-dyyb, the majority switched from IFX-REF or a non-IFX biologic/tsDMARD. CDAI remained stable in patients switching from IFX-REF/IFX biosimilar and improved in patients switching from a non-IFX biologic/tsDMARD and in biologic/tsDMARD-naïve patients.

Keyphrases

end stage renal disease
ejection fraction
rheumatoid arthritis
newly diagnosed
chronic kidney disease
prognostic factors
type diabetes
patient reported outcomes
adipose tissue
systemic lupus erythematosus
systemic sclerosis
weight loss
interstitial lung disease
idiopathic pulmonary fibrosis